慢性丙型肝炎治疗新纪元——口服逆转录酶和蛋白酶抑制剂的临床应用

丁洋; 夏婷婷; 窦晓光

慢性丙型肝炎治疗新纪元——口服逆转录酶和蛋白酶抑制剂的临床应用

中国医科大学附属盛京医院感染科

基金项目:

国家“十一五”传染病重大专项课题(2008ZX10206)；辽宁省科学技术计划重大、重点项目(2009225010-7)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 4067
- HTML全文浏览量: 16
- PDF下载量: 889
- 被引次数: 0
出版历程
- 出版日期: 2011-12-20

New era for management of HCV:Oral combination of a nucleoside polymerase inhibitor and protease inhibitor

Research funding:

摘要

摘要: 慢性丙型肝炎患者经过聚乙二醇干扰素（PEG-IFN）联合利巴韦林（RBV）治疗后,多数患者可以获得临床治愈,即停药随访6个月后病毒仍然检测不到,且疾病不再进展。然而,还有相当一部分患者因为不能耐受IFN或RBV而未完成标准治疗,或对治疗完全无应答,或停药后复发,或由于疾病发现较晚而失去了抗病毒治疗的时机。因此,在临床上仍然需要新的抗病毒药物,或者和IFN联合治疗,或者单独治疗。本文将就近年来研发的口服逆转录酶和蛋白酶抑制剂的直接抗病毒药物的临床研究和应用作一综述。
- 肝炎,丙型,慢性 /
- 逆转录酶抑制剂 /
- 蛋白酶抑制剂 /
- 投药,口服 /
- 药物疗法,联合
Abstract: Chronic hepatitis C, a curable disease with pegylated interferon alfa (PEG-IFN) plus ribavirin (RBV) , has been associated with rates of sustained virological response (SVR) , which is defined as HCV RNA negative at 24 weeks after cessation of treatment and the disease is not or slow progressive.While some patients have lower tolerability towards either IFN or RBV due to side effects, or null non-response to treatment, or relapse after cessation of treatment, or in late stage of the disease.Many direct-acting antiviral drugs are being developed that are aimed at various HCV targets.The successful development of an oral interferon-free direct-acting antiviral drug combination treatment would fill an unmet medical need, and potentially change the existing standard of care for HCV.
- hepatitis C /
- chronic /
- reverse transcriptase inhibiors /
- protease inhibitor /
- administration

HTML全文

参考文献(9)

[1]Herber E, Harris C, Hernandez C.Efficient hepatitis C virus particle formation requires diacylglyceral acyltransferase-1[J].Nat med, 2010, 16 (11) :1295-1298.

[2]Jacobson IM, McHutchison JG, Dusheiko G, et al.Telapre-vir for Previously Untreated Chronic Hepatitis C Virus Infec-tion[J].N Engl J Med, 2011, 364 (25) :2405-2416.

[3]Poordad F, McCone JJr, Bacon BR, et al.Boceprevir for Untreated Chronic HCV Genotype1Infection[J].NEJM, 2011, 364 (13) :1195-1206.

[4]Zeuzem S, Andreone P, Pol S, et al.Telaprevir for Retreat-ment of HCV Infection[J].NEJM, 364 (25) :2417-2428.

[5]Bacon BR, Gordon SC, Lawitz E, et al.Boceprevir for Previ-ously Treated Chronic HCV Genotype1Infection[J].N Engl J, 2011, 364 (13) :1207-1217.

[6]Lindenbach BD, Rice CM.Unravelling hepatitis C virus repli-cation from genome to function[J].Nature, 2005, 436 (18) :2005:933-938.

[7]Gane E, Robers SK, Stedman CA, et al.Oral combinantion therapy with a nucleoside polymerase inhibitor CRG7128and danoprevir for chronic hepatitis C genotype1infection:arandomised, double-blind, placebo-controlled, dose-es-calation trail[J].Lancet, 2010, 376 (9751) :1467-1475.

[8]Di Bisceglie AM, Nelson DR, Gane E, et al.VX-222with TVR alone or in combination with PEG-IFN alfa-2A and RBV in treatment-nave patients with chronic hepatitis C:ZENITH study interim results[J].J Hepatol, 2011, 54:S535-S546.

[9]Lok A, Gardiner D, Lawitz E, et al.Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100%SVR12 in HCV Genotype 1null re-sponders[C].EASL 46th Annual Meeting, Berlin, 2011.

施引文献

资源附件(0)

访问统计